Back to Interventions

Substance / Medication

Daclizumab

SNOMED 386977009 UMLS C0663182

Overview

Active Ingredient

daclizumab

RxNorm CUI

190353

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Multiple sclerosis

Graft versus host disease

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Calcidiol+ercalcidiol

LOINC 14635-7

secondary

LOINC 2132-9

secondary

LOINC 26464-8

secondary

Clinical Trials

14 trials linked to this intervention

14

Total Trials

0

Recruiting

6

With Results

Recent Trials

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

NCT00685061Phase 4Completed90 enrolled

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

NCT01172418Phase 4Completed200 enrolled

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

NCT00681343Phase 4Completed38 enrolled

CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

NCT00246129Phase 4Completed123 enrolled

Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD

NCT00574470Phase 4Completed3 enrolled

View all 14 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Daclizumab for relapsing remitting multiple sclerosis.

Liu Jia, Wang Lu-Ning, Zhan Siyan et al. · Cochrane Database Syst Rev · 2013

PMID: 24363032Meta-AnalysisFull text (PMC)

Daclizumab for relapsing remitting multiple sclerosis.

Liu Jia, Wang Luning, Zhan Si-Yan et al. · Cochrane Database Syst Rev · 2012

PMID: 22513956Meta-Analysis

The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.

Hao W-J, Zong H-T, Cui Y-S et al. · Transplant Proc · 2012

PMID: 23195005Meta-Analysis

Daclizumab for relapsing remitting multiple sclerosis.

Liu Jia, Wang Luning, Zhan Siyan et al. · Cochrane Database Syst Rev · 2010

PMID: 20556791Meta-Analysis

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.

Cohan Stanley, Kappos Ludwig, Giovannoni Gavin et al. · Mult Scler · 2018

PMID: 28984179RCTFull text (PMC)

Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up.

Ciancio Gaetano, Gaynor Jeffrey J, Guerra Giselle et al. · Transpl Immunol · 2017

PMID: 27888093RCT

Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.

Phillips Glenn, Guo Shien, Bender Randall et al. · Mult Scler Relat Disord · 2016

PMID: 27063626RCT

Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.

Radue E-W, Sprenger T, Vollmer T et al. · Eur J Neurol · 2016

PMID: 26806217RCT

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.

Giovannoni Gavin, Radue Ernst-Wilhelm, Havrdova Eva et al. · J Neurol · 2014

PMID: 24375015RCTFull text (PMC)

Combination of a low dose of daclizumab and standard regimen for prevention of rejection in men and women receiving a kidney transplant.

Sohrevardi Seyed Mojtaba, Azmandian Jalal, Shafii Zahra et al. · Iran J Kidney Dis · 2013

PMID: 23485539RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Neurology Physician

Psychiatry & Neurology — Neurology

NUCC 2084N0400X

Find a Provider

Health Goals

Goals connected through associated conditions

Manage Autoimmune Risk

Quick Facts

Type: Substance / Medication
Fully Specified Name: Daclizumab (substance)
SNOMED CT: 386977009
UMLS CUI: C0663182
RxNorm CUI: 190353

Clinical Data

This intervention maps to 7 entities in the Healos knowledge graph.

2

Conditions

3

Biomarkers

1

Specialists

0

Symptoms

14

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.